ImmunityBio, Inc. IBRX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s retained earnings?
- ImmunityBio, Inc. (IBRX) reported retained earnings of -$4.36B in Q1 2026.
- How has ImmunityBio, Inc.'s retained earnings changed year-over-year?
- ImmunityBio, Inc.'s retained earnings decreased by 24.4% year-over-year, from -$3.5B to -$4.36B.
- What is the long-term trend for ImmunityBio, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s retained earnings has grown at a 18.2% compound annual growth rate (CAGR), from -$1.62B to -$3.73B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.